Auriga Laboratories Announces FDA Approval of Liquadd(TM) (Dextroamphetamine Sulfate) Oral Solution for the Treatment of ADHD and Upcoming Product Launch
Mar 10, 2008 8:30:00 AM
View Additional ProfilesCAMARILLO, CA -- (MARKET WIRE) -- 03/10/08 -- Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company, announced today the FDA approval of Liquadd(TM) (dextroamphetamine sulfate) Oral Solution 5 mg/5 mL indicated for the treatment of Attention Deficit Disorder with Hyperactivity (ADHD).
The ADHD market is valued at over $3.5 billion dollars, with approximately 35 million prescriptions written annually. Dextroamphetamine is one of the most frequently prescribed molecules for the treatment of ADHD. "Liquadd(TM) will now provide physicians the proven efficacy of dextroamphetamine in a unique new oral solution form, with our key target consisting of the estimated 5% to 10% of patients that have difficulty swallowing pills. We are excited about expanding the treatment options available to physicians by providing a dextroamphetamine treatment regimen in an easy to swallow form previously not available in the market," said Rick Coulon, Executive Vice President of Sales and Marketing of Auriga.
Liquadd(TM) will be launched during the 2nd Quarter of 2008. "This new product further solidifies Auriga's commitment to enhance our product portfolio. Currently, we promote several of our products to psychiatrists and pediatricians, and Liquadd(TM) will be a highly synergistic addition to Auriga's current promotional efforts in these specialties," said Frank Greico, Chief Executive Officer of Auriga
Market Data 
Markets 
AI
